Huahai Pharmaceutical (600521.SH) issued a profit forecast increase, expecting net profit attributable to shareholders for the first three quarters to be 1.028 billion yuan to 1.103 billion yuan, a year-on-year increase of approximately 170% to 190%.

Zhitong Finance APP News, Huahai Pharmaceutical (600521.SH) released a pre-increase announcement for its performance for the first three quarters of 2026. The company is expected to achieve net profit attributable to shareholders of the listed company of between RMB 1.028 billion and RMB 1.103 billion for the first three quarters of 2026, a year-on-year increase of approximately 170% to 190%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between RMB 662 million and RMB 743 million, a year-on-year increase of approximately 145% to 175%.